Recombinant CD1a antibody (full length)

Catalog No. ABIN7877848

The Mouse Monoclonal anti-CD1a antibody (Clone rC1A-8110) (ABIN7877848) specifically detects CD1a in IHC (p). The antibody is reactive with Human samples.

Quick Overview for Recombinant CD1a antibody (full length) (ABIN7877848)

Target: CD1a

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD1a antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: RC1A-8110

Product Details anti-CD1a Antibody

Binding Specificity: full length

Purpose: CD1a Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human CD1a protein was used as the immunogen for the CD1a antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the CD1a antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the CD1a antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CD1a

Target: CD1a

Alternative Name: CD1a

Background: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

UniProt: P06126

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process